Overview

Cannabinol Use in Patients With Insomnia Disorder

Status:
Not yet recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus placebo, on sleep architecture and next-day functioning in adults aged 25-65 years with chronic insomnia disorder.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Woolcock Institute of Medical Research

Collaborator:

University of Sydney